Follow CGSP on Social Media

Listen to the CGSP Podcast

FT: The Evidence From Chile Says Sinovac’s Vaccine is Working

by Eric Olander

Despite earlier concerns over its low efficacy rate, the Chinese-made Sinovac COVID-19 vaccine appears to be performing well in its largest test to date in Chile, according to the findings by the Financial Times’ Senior Data-Visualization Journalist John Burn-Murdoch.

Sinovac’s 50.4% efficacy rate that was derived from phase three clinical trials in Brazil, related to mild cases only. What Burn-Murdoch’s reporting shows is that the vaccine is successfully protecting people from becoming seriously ill and keeping them out of the intensive care unit.

  • Get a daily email packed with the latest China-Africa news and analysis.
  • Read exclusive insights on the key trends shaping China-Africa relations.
  • Full access to the News Feed that provides daily updates on Chinese engagement in Africa and throughout the Global South.

China, Africa and the Global South... find out what’s happening.

Subscribe today for unlimited access.

OR

Already a subscriber? Log in Click Here to Learn More

You Might Like

Deborah Bräutigam: China Likely To Partner With the WHO For C19 Vaccine Distribution in Africa

China is working closely with Ethiopia, Egypt, and likely other African countries to lay the groundwork to deliver millions of doses of COVID-19 vaccines to the continent. With the new cold-chain air ...

China Will Have to Pick Up the Pace If It Wants to Achieve Its Billion-Vaccine Pledge in Africa

Chinese vaccine deliveries to Africa remain among the smallest and slowest of any region in the world, particularly compared to distribution in the Asia-Pacific region where almost a billion doses have already been delivered. So ...

In a Potentially Troubling Development for Africa, Sinovac Did Not Perform Well in Early Test Against Omicron Variant

Researchers at the University of Hong Kong (HKU) found that people inoculated with two doses of Sinovac’s COVID-19 vaccine did not produce sufficient detectable levels of antibodies needed to fend off the new ...

What is The China-Africa Project?

Independent

The CAP is passionately independent, non-partisan and does not advocate for any country, company or culture.

News

A carefully curated selection of the day’s most important China-Africa stories. Updated 24 hours a day by human editors. No bots, no algorithms.

Analysis

Diverse, often unconventional insights from scholars, analysts, journalist and a variety of stakeholders in the China-Africa discourse.

Networking

A unique professional network of China-Africa scholars, analysts, journalists and other practioners from around the world.

Subscribe